Please login to the form below

Not currently logged in

Sanofi appoints Meeker CEO of Genzyme

Current chief operating officer of Genzyme, David Meeker, will take over as CEO of the company from November 1

Current chief operating officer of Genzyme, David Meeker, will take over as CEO of the company from November 1.

He was appointed by France-based pharmaceutical company Sanofi who purchased Genzyme in April 2011 for about $20bn.

Former Genzyme CEO, Henri A Termeer, who had spent 26 years in the position, left Genzyme following the takeover. The company had since been without a CEO until Meeker's appointment.

Christopher A Viehbacher, CEO of Sanofi, said: "After working closely with David over the past six months, I am confident that he is the best person to lead Genzyme. David's commitment to employees, physicians and patients has been a key success factor in the successful integration of Genzyme as part of the Sanofi Group."

Under Meeker's leadership, Genzyme will incorporate the rare disease business and the multiple sclerosis franchise.

Previous Genzyme divisions - renal, biosurgery and oncology - have been integrated within the existing Sanofi portfolio.

Meeker joined Genzyme in 1994 as medical director to work on the cystic fibrosis gene therapy programme. Other positions Meeker held at Genzyme include president of the global rare disease business.

25th October 2011


Featured jobs

Subscribe to our email news alerts


Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...